Three more recipients awarded funding assistance to pursue translational medicine research at Harvard Medical School
“We congratulate the second group of Fujifilm Fellows who represent the best and brightest young minds intent on solving urgent, unmet medical needs,” said Yutaka Yamaguchi, general manager of the Fujifilm Life Science Strategic Business Office. “With our long history of innovation, Fujifilm is deeply committed to supporting the educational and research efforts of high achievers striving to make significant breakthroughs in the life sciences.”
The second cohort of Fujifilm Fellowship recipients includes:
Wai Cheung (Adrian) Chan—Chan is enrolled in Harvard’s Chemical Biology Ph.D. program and is a student at two labs at the Dana-Farber Cancer Institute. Chan’s work holds promise towards first-in-class drugs targeting deubiquitinating enzymes (DUBs), medicinal chemistry insights for what makes a good DUB inhibitor, as well as a generalizable chemoproteomic platform applicable to other target classes.
Alyssa Larios—Larios is currently enrolled in Harvard’s Neuroscience Ph.D. program. Her research explores the link between the loss of dopamine neurons and motor deficits in Parkinson’s disease. Her ultimate goal is to uncover novel strategies for symptom management and therapeutic treatment in Parkinson’s patients.
Yingxiao (TK) Shi—Shi is enrolled in Harvard’s Biological and Biomedical Sciences Ph.D. Program, Shi is presently part of a lab that focuses on developing systematic approaches to determine and characterize genes that drive cancer initiation, progression, and tumor maintenance. Shi’s goal is to better understand different clones within one tumor as well as each clone’s role in tumor formation, which would allow for the development of effective combination treatments to treat cancer systematically.
Established through a gift of $1,000,000 the Fujifilm Fellowship program was designed by Fujifilm and HMS to advance translational medicine research by investing in future therapeutics innovators. The selected beneficiaries who have been admitted to Harvard Medical School’s Therapeutics Graduate Program will receive financial assistance to pursue their education and research in therapeutic innovation. The program is expected to support the six Fujifilm Fellows until the summer of 2021. HMS leadership selects all program beneficiaries.
The Fujifilm Fellowship program is one of several translational medicine programs between Harvard University and FUJIFILM Group Companies. In 2019, FUJIFILM Diosynth Biotechnologies joined Harvard University, Massachusetts Institute of Technology (MIT), GE Healthcare Life Sciences and Alexandria Real Estate Equities as founding members of a Center of Innovation and Manufacturing in Boston, Massachusetts, in collaboration with area hospitals.
“Fujifilm has been developing a broad and collaborative partnership with Harvard University which is spanning several divisions, schools and institutes. We are continuing to build on these programs together to accelerate Life Science innovation into the community,” said Bruce E. Novich, Sc.D., division president, FUJIFILM Holdings America Corporation.
For more information, please visit https://www.fujifilmhealthcare.com/life-sciences-strategy
FUJIFILM Holdings America Corporation is the regional headquarters for the Americas. It is comprised of 21 affiliate companies across North and Latin America. The company manufactures, markets and provides service for a broad spectrum of industries including photographic, medical imaging and informatics, pharmaceutical, regenerative medicine, and biopharmaceutical contract manufacturing. Industrial segments include data storage, electronic materials, chemical, industrial testing products, and graphic arts products and services. For more information, please visit: https://www.fujifilm.com/us/en/about/region.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.